COPD trials recruiting in North Carolina

All COPD trials nationally

Cities in North Carolina

Recruiting trials in North Carolina

• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
  NCT06283966 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · North Carolina: Fayetteville, Greensboro, Greenville, Huntersville
• A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)
  NCT07646587 · Phase: Phase 2 · Ages: 40 Years to 80 Years · Sex: All (male and female) · North Carolina: Charlotte
• A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
  NCT07053423 · Phase: Phase 4 · Ages: 40 Years to 85 Years · Sex: All (male and female) · North Carolina: Charlotte, Winston-Salem
• A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
  NCT07082738 · Phase: Phase 2 · Ages: 40 Years and older · Sex: All (male and female) · North Carolina: New Bern
• A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
  NCT06883305 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · North Carolina: High Point, Kings Mountain, New Bern, Wilmington
• A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
  NCT06878261 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · North Carolina: Charlotte, Concord, Fayetteville
• A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
  NCT07363694 · Phase: Phase 2, Phase 3 · Ages: 35 Years to 80 Years · Sex: All (male and female) · North Carolina: Winston-Salem
• A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease
  NCT06603246 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Chapel Hill
• Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
  NCT07059091 · Phase: Phase 2 · Ages: 40 Years and older · Sex: All (male and female) · North Carolina: Durham
• Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
  NCT06122077 · Phase: Not specified · Ages: 50 Years and older · Sex: All (male and female) · North Carolina: Raleigh
• Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
  NCT06961214 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · North Carolina: Shelby
• Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
  NCT07190209 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · North Carolina: Hickory, Winston-Salem
• Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
  NCT07190222 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · North Carolina: Greenville, Statesville, Winston-Salem
• Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD
  NCT07051707 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years to 80 Years · Sex: All (male and female) · North Carolina: Salem
• Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia
  NCT07037836 · Phase: Phase 2 · Ages: 40 Years and older · Sex: All (male and female) · North Carolina: Durham
• Nebulizer Versus Handheld Maintenance Therapy for Patients With COPD
  NCT07816835 · Phase: Phase 4 · Ages: 60 Years and older · Sex: All (male and female) · North Carolina: Winston-Salem
• Photon-counting CT in Chest Imaging
  NCT07031336 · Phase: Not applicable (e.g. observational or device study) · Ages: No age limits stated · Sex: All (male and female) · North Carolina: Durham
• Pulmonary Hypertension SOLAR
  NCT04778046 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Durham
• SPIROMICS Study of Early COPD Progression (SOURCE)
  NCT05033990 · Phase: Not specified · Ages: 30 Years to 55 Years · Sex: All (male and female) · North Carolina: Winston-Salem
• STRIVE Post-Market Registry Study
  NCT04302272 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Durham
• The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry
  NCT07612878 · Phase: Not specified · Ages: 40 Years and older · Sex: All (male and female) · North Carolina: Durham
• To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
  NCT07684820 · Phase: Phase 2 · Ages: 40 Years to 85 Years · Sex: All (male and female) · North Carolina: Shelby
• Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD
  NCT07610395 · Phase: Phase 2 · Ages: 40 Years to 85 Years · Sex: All (male and female) · North Carolina: Kings Mountain
• Validation of Chronic Obstructive Pulmonary Disease (COPD) Algorithm
  NCT07223749 · Phase: Not specified · Ages: 40 Years and older · Sex: All (male and female) · North Carolina: Winston-Salem
• eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
  NCT07177339 · Phase: Phase 3 · Ages: 40 Years to 75 Years · Sex: All (male and female) · North Carolina: Winston-Salem